|
1) Zipursky A. Transient leukaemia-a benign form of leukaemia in newborn infants with trisomy 21. Br J Haematol. 2003; 120: 930-8
|
|
|
|
2) Pine SR, Guo Q, Yin C, et al. Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome. Blood. 2007; 110: 2128-31
|
|
|
|
|
|
3) Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryo-blastic leukemia of Down syndrome. Nat Genet. 2002; 32: 148-52
|
|
|
|
|
|
4) Xu G, Nagano M, Kanezaki R, et al. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood. 2003; 102: 2960-8
|
|
|
|
|
|
5) Klusmann JH, Godinho FJ, Heitmann K, et al. Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis. Genes Dev. 2010; 24: 1659-72
|
|
|
|
|
|
6) Kanezaki R, Toki T, Terui K, et al. Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia. Blood. 2010; 116: 4631-8
|
|
|
|
|
|
7) Ito E, Kasai M, Hayashi Y, et al. Expression of erythroid-specific genes in acute megakaryo-blastic leukaemia and transient myeloproliferative disorder in Downʼs syndrome. Br J Haematol. 1995; 90: 607-14
|
|
|
|
|
|
8) Calligaris R, Bottardi S, Cogoi S, et al. Alternative translation initiation site usage results in two functionally distinct forms of the GATA-1 transcription factor. Proc Natl Acad Sci U S A. 1995; 92: 11598-602
|
|
|
|
|
|
9) Rainis L, Bercovich D, Strehl S, et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood. 2003; 102: 981-6
|
|
|
|
|
|
10) Halsey C, Tunstall O, Gibson B, et al. Role of GATA-1s in early hematopoiesis and differences between alternative splicing in human and murine GATA-1. Blood. 2010; 115: 3415-6
|
|
|
|
|
|
11) Alford KA, Reinhardt K, Garnett C, et al. Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia. Blood. 2011; 118: 2222-38
|
|
|
|
|
|
12) Muntean AG, Crispino JD. Differential requirements for the activation domain and FOG-interaction surface of GATA-1 in megakaryocyte gene expression and development. Blood. 2005; 106: 1223-31
|
|
|
|
|
|
13) Kuhl C, Atzberger A, Iborra F, et al. GATA1-mediated megakaryocyte differentiation and growth control can be uncoupled and mapped to different domains in GATA1. Mol Cell Biol. 2005; 25: 8592-606
|
|
|
|
|
|
14) Kadri Z, Shimizu R, Ohneda O, et al. Direct binding of pRb/E2F-2 to GATA-1 regulates maturation and terminal cell division during erythropoiesis. PLoS Biol. 2009; 7: e1000123
|
|
|
|
|
|
15) Korbel JO, Tirosh-Wagner T, Urban AE, et al. The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies. Proc Natl Acad Sci U S A. 2009; 106: 12031-6
|
|
|
|
|
|
16) Rainis L, Toki T, Pimanda JE, et al. The proto-oncogene ERG in megakaryoblastic leukemias. Cancer Res. 2005; 65: 7596-602
|
|
|
|
|
|
17) Ng AP, Hyland CD, Metcalf D, et al. Trisomy of Erg is required for myeloproliferation in a mouse model of Down syndrome. Blood. 2009; 115: 3966-9
|
|
|
|
|
|
18) Salek-Ardakani S, Smooha G, de Boer J, et al. ERG is a megakaryocytic oncogene. Cancer Res. 2009; 69: 4665-73
|
|
|
|
|
|
19) Stankiewicz MJ, Crispino JD. ETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hemato-poietic progenitor cells. Blood. 2009; 113: 3337-47
|
|
|
|
|